Literature DB >> 18025122

Novel lamivudine resistance.

Oliver Schildgen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18025122      PMCID： PMC2168002          DOI： 10.1128/AAC.00840-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection.

Authors:  B Ni Laoi; C Herra; S Norris; B Crowley
Journal:  J Antimicrob Chemother       Date:  2007-03-01       Impact factor: 5.790

Review 2.  Antiviral therapy and resistance with hepatitis B virus infection.

Authors:  Hans L Tillmann
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Variant of hepatitis B virus with primary resistance to adefovir.

Authors:  Oliver Schildgen; Hueseyin Sirma; Anneke Funk; Cynthia Olotu; Ulrike C Wend; Heinz Hartmann; Martin Helm; Jürgen K Rockstroh; Wulf R Willems; Hans Will; Wolfram H Gerlich
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

4.  Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.

Authors:  N Ogata; K Fujii; S Takigawa; M Nomoto; T Ichida; H Asakura
Journal:  J Med Virol       Date:  1999-11       Impact factor: 2.327

5.  Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure.

Authors:  S Günther; F von Breunig; T Santantonio; M C Jung; G B Gaeta; L Fischer; M Sterneck; H Will
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

6.  Mutagenic DNA polymerase.

Authors:  J F Speyer
Journal:  Biochem Biophys Res Commun       Date:  1965-10-08       Impact factor: 3.575

7.  The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

Authors:  Nadia Warner; Stephen Locarnini; Michael Kuiper; Angeline Bartholomeusz; Anna Ayres; Lilly Yuen; Tim Shaw
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

8.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

Authors:  Marie-Noëlle Brunelle; Anne-Carole Jacquard; Christian Pichoud; David Durantel; Sandra Carrouée-Durantel; Jean-Pierre Villeneuve; Christian Trépo; Fabien Zoulim
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

9.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

Authors:  William E Delaney; Huiling Yang; Christopher E Westland; Kalyan Das; Eddy Arnold; Craig S Gibbs; Michael D Miller; Shelly Xiong
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.